-+ 0.00%
-+ 0.00%
-+ 0.00%

Crescent Biopharma presents ASCEND Phase 1/2 CR-001 trial-in-progress at ASCO 2026

PUBT·05/21/2026 21:33:41
Listen to the news
Crescent Biopharma presents ASCEND Phase 1/2 CR-001 trial-in-progress at ASCO 2026
  • Crescent Biopharma will present a trial-in-progress poster at the ASCO 2026 Annual Meeting on May 30 for ASCEND, its Phase 1/2 study of CR-001 in locally advanced or metastatic solid tumors.
  • The program is positioned as an early-stage test of CR-001’s safety profile, dose selection strategy, and initial signs of anti-tumor activity across several tumor settings.
  • Enrollment is ongoing for a global, open-label study expected to include up to 290 patients across dose-escalation, backfill, and dose-optimization cohorts.
  • Initial proof-of-concept readouts are slated to begin in Q1 2027, with additional updates on combinations with standard chemotherapy or an antibody-drug conjugate planned for mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.